Back to Trials
NCT05575440Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Mayo Clinic

Start Date

4/22/2022

Completion Date

5/1/2028

Summary

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Detailed Description

PRIMARY OBJECTIVES: I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard. II. Assess the impact of 18F-TFB PET/CT on clinical management. OUTLINE: Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Subject has biopsy-proven papillary or follicular thyroid cancer * Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan * Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan * Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent) * Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min) * Age 18 or older * Ability to understand a written informed consent document, and the willingness to sign it * Subject is not pregnant Exclusion Criteria: * Contrast-enhanced CT within 4 last weeks * Amiodarone within last 4 months * Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks * Unable to lie flat, still or tolerate a PET scan * Applied betadine, iodoform, or quick tanning products to skin within last two weeks * If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25 * Taken anti-thyroid medication within 1 week * Subject is breastfeeding * Positive pregnancy test

Interventions

PROCEDURE

Computed Tomography

RADIATION

Fluorine F 18 Tetrafluoroborate

PROCEDURE

Positron Emission Tomography

OTHER

Survey Administration

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Differentiated Thyroid Gland CarcinomaThyroid Gland Follicular CarcinomaThyroid Gland Papillary Carcinoma

Locations

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States